Table of Contents - Espicom

More documents

Recommendations

Info

Table of Contents xii Diabetes Landscape: Priority Date by Year by Assignee: .....................................................................................................................................................319 Figure 5.37 - Interstitial Fluid by Priority Date ........................................................................................................................................................................................... 319 Published Date by Year: ...................................................................................................................................................................... 320 Figure 5.38 - Interstitial Fluid by Published Date ....................................................................................................................................................................................... 320 IPC Analysis - Top 10 Codes: ...............................................................................................................................................321 Figure 5.39 - Interstitial Fluid by IPC Code .................................................................................................................................................................................................. 321 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 322 Figure 5.40 - Interstitial Fluid by USPC Code ............................................................................................................................................................................................... 322 Text Clustering Analysis: ..................................................................................................................................................................... 323 Figure 5.41 – Interstitial Fluid - Text Clustering Analysis ........................................................................................................................................................................... 323 Source Jurisdiction: .............................................................................................................................................................................. 324 Figure 5.42 - Interstitial Fluid by Source Jurisdiction .................................................................................................................................................................................. 324 Top Patents ............................................................................................................................................................................................ 325 Table 5.4 - Top Patents Identified in the Interstitial Fluid Group ................................................................................................................................................................ 325 US5582184: Alere Incorporated ......................................................................................................................................326 Figure 5.43 – Representative Image in US5582184 ................................................................................................................................................................................... 326 Figure 5.44 – Top 20 Companies Citing US5582184 .................................................................................................................................................................................. 327 5.5 Detection and Monitoring – Periodic – Minimally Invasive – Skin Diffusion ............................................................ 328 Figure 5.45 – Skin Diffusion – Top Assignees ............................................................................................................................................................................................ 328 Priority Date by Year: ........................................................................................................................................................................... 329 Figure 5.46 - Skin Diffusion by Priority Date .............................................................................................................................................................................................. 329 Priority Date by Year by Assignee: .................................................................................................................................................... 329 Figure 5.47 - Skin Diffusion by Priority Date by Assignee ........................................................................................................................................................................... 329 Published Date by Year: ...................................................................................................................................................................... 330 Figure 5.48 - Skin Diffusion by Published Date .......................................................................................................................................................................................... 330 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 331 Figure 5.49 - Skin Diffusion by IPC Code ..................................................................................................................................................................................................... 331 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 332 Figure 5.50 - Skin Diffusion by USPC Code .................................................................................................................................................................................................. 332 Text Clustering Analysis: ..................................................................................................................................................................... 333 Figure 5.51 – Skin Diffusion - Text Clustering Analysis .............................................................................................................................................................................. 333 Source Jurisdiction: .............................................................................................................................................................................. 334 Figure 5.52 - Skin Diffusion by Source Jurisdiction ..................................................................................................................................................................................... 334 Top Patents ............................................................................................................................................................................................ 334 Table 5.5 - Top Patents Identified in the Skin Diffusion Group ................................................................................................................................................................... 334 US6454710: Johnson & Johnson ......................................................................................................................................335 Figure 5.53 – Representative Image in US6454710 ................................................................................................................................................................................... 335 Figure 5.54 – Top 20 Companies Citing US6454710 .................................................................................................................................................................................. 336 5.6 Detection and Monitoring – Periodic – Non Invasive – Optical................................................................................... 337 Figure 5.55 – Non Invasive - Optical – Top Assignees ............................................................................................................................................................................... 337 Priority Date by Year: ........................................................................................................................................................................... 338 Figure 5.56 - Non Invasive - Optical by Priority Date .................................................................................................................................................................................. 338 Priority Date by Year by Assignee: .................................................................................................................................................... 338 Figure 5.57 - Non Invasive - Optical by Priority Date .................................................................................................................................................................................. 338 Published Date by Year: ...................................................................................................................................................................... 339 Figure 5.58 - Non Invasive - Optical by Published Date .............................................................................................................................................................................. 339 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 340 Figure 5.59 - Non Invasive - Optical by IPC Code ........................................................................................................................................................................................340 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 341 Figure 5.60 - Non Invasive - Optical by USP Class Code .............................................................................................................................................................................. 341 Text Clustering Analysis: ..................................................................................................................................................................... 342 Figure 5.61 – Non Invasive - Optical - Text Clustering Analysis ................................................................................................................................................................. 342 Source Jurisdiction: .............................................................................................................................................................................. 343 Figure 5.62 - Non Invasive - Optical by Source Jurisdiction ........................................................................................................................................................................ 343 Top Patents ............................................................................................................................................................................................344 © Espicom Business Intelligence © 2012 UBM Semiconductor Insights May 2012
Diabetes Landscape: May 2012 © Espicom Business Intelligence © 2012 UBM Semiconductor Insights Table of Contents Table 5.6- Top Patents Identified in the Non Invasive Optical Group .........................................................................................................................................................344 US5743262: Masimo Corporation ................................................................................................................................... 345 Figure 5.63 – Representative Image in US5743263 ................................................................................................................................................................................... 345 Figure 5.64 – Top 20 Companies Citing US5743263 ...................................................................................................................................................................................346 US6040578: Sensys Medical Inc ........................................................................................................................................347 Figure 5.65 – Patent Diagram of US6040578 ............................................................................................................................................................................................ 347 Figure 5.66 – Top 20 Companies Citing US6040578 ..................................................................................................................................................................................348 5.7 Detection and Monitoring – Periodic – Non Invasive – Other .....................................................................................349 Figure 5.67 – Non-Invasive Other – Top Assignees ...................................................................................................................................................................................349 Priority Date by Year: ........................................................................................................................................................................... 350 Figure 5.68 – Non-Invasive Other by Priority Date .................................................................................................................................................................................... 350 Priority Date by Year by Assignee: .................................................................................................................................................... 350 Figure 5.69 - Non-Invasive Other by Priority Date by Assignee.................................................................................................................................................................. 350 Published Date by Year: ...................................................................................................................................................................... 351 Figure 5.70 - Non-Invasive Other by Published Date ................................................................................................................................................................................. 351 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 352 Figure 5.71 - Non Invasive Other by IPC Code ............................................................................................................................................................................................. 352 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 353 Figure 5.72 - Non Invasive Other by USPC Code.......................................................................................................................................................................................... 353 Text Clustering Analysis: ..................................................................................................................................................................... 354 Figure 5.73 – Non Invasive Other - Text Clustering Analysis ...................................................................................................................................................................... 354 Source Jurisdiction: .............................................................................................................................................................................. 355 Figure 5.74 – Non-Invasive - Other by Source Jurisdiction ........................................................................................................................................................................ 355 Top Patents ............................................................................................................................................................................................ 355 Table 5.7 - Top Patents Identified in the Non Invasive – Other Group ....................................................................................................................................................... 355 US6572542: Medtronic Inc ................................................................................................................................................356 Figure 5.75 – Representative Image in US6572542 ................................................................................................................................................................................... 356 Figure 5.76 – Top 20 Companies Citing US6572542 .................................................................................................................................................................................. 357 5.8 Detection and Monitoring – Continuous – Non-Implanted ........................................................................................ 358 Figure 5.77 – Continuous Non-Implanted – Top Assignees ...................................................................................................................................................................... 358 Priority Date by Year: ........................................................................................................................................................................... 359 Figure 5.78 - Continuous Non-Implanted by Priority Date ........................................................................................................................................................................ 359 Priority Date by Year by Assignee: .................................................................................................................................................... 359 Figure 5.79 - Continuous Non-Implanted by Priority Date by Assignee .................................................................................................................................................... 359 Published Date by Year: ...................................................................................................................................................................... 360 Figure 5.80 - Continuous Non-Implanted by Published Date ....................................................................................................................................................................360 IPC Analysis – Top 10 Codes: ............................................................................................................................................................... 361 Figure 5.81 - Continuous Non-Implanted by IPC Code ............................................................................................................................................................................... 361 USPC Analysis – Top 10 Codes: ........................................................................................................................................................... 362 Figure 5.82 - Continuous Non-Implanted by USPC Code ...........................................................................................................................................................................362 Figure 5.83 – Continuous Non-Implanted -Text Clustering Analysis ......................................................................................................................................................... 363 Source Jurisdiction: .............................................................................................................................................................................. 364 Figure 5.84 - Continuous Non-Implanted by Source Jurisdiction ..............................................................................................................................................................364 Top Patents ............................................................................................................................................................................................ 365 Table 5.8 - Top Patents Identified in the Continuous Non-Implanted Group ............................................................................................................................................. 365 US6931327: Dexcom, Inc. ................................................................................................................................................. 366 Figure 5.85 – Representative Image in US6931327 ...................................................................................................................................................................................366 Figure 5.86 – Top 20 Companies Citing US6931327 ................................................................................................................................................................................... 367 5.9 Detection and Monitoring – Continuous – Implanted ..................................................................................................368 Figure 5.87 – Continuous Implanted – Top Assignees ..............................................................................................................................................................................368 Priority Date by Year: ........................................................................................................................................................................... 369 Figure 5.88 - Continuous Implanted by Priority Date ................................................................................................................................................................................ 369 Priority Date by Year by Assignee: .................................................................................................................................................... 369 Figure 5.89 - Continuous Implanted by Priority Date by Assignee ............................................................................................................................................................. 369 Published Date by Year: ...................................................................................................................................................................... 370 xiii
Page 1 and 2: DIABETES LANDSCAPE Market, Technolo
Page 3 and 4: Diabetes Landscape: CONTENTS Table
Page 5 and 6: Diabetes Landscape: May 2012 © Esp
Page 11: Diabetes Landscape: May 2012 © Esp
Page 17 and 18: Diabetes Landscape: Table of Conten

Table of Contents - Espicom

Create successful ePaper yourself

Delete template?

Save as template?